Plate Nº 44 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Stanford Medicine: 1 in 10 People May Resist GLP-1 Diabetes Drugs
Stanford Medicine reports that roughly 1 in 10 people may resist GLP-1 diabetes drugs, a class that includes Ozempic and Mounjaro. The finding raises questions about alternative treatments for non-responders.
By James Calloway3 min read529 words
In brief
- Stanford Medicine headline: about 1 in 10 people (10%) may have resistance to GLP-1 diabetes drugs
- GLP-1 receptor agonists include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)
- Type 2 diabetes affects more than 500 million adults worldwide, per the International Diabetes Federation
- Hemoglobin A1C, a 3-month blood-sugar average, is the standard measure doctors use to judge drug response
- U.S. GLP-1 prescriptions have surpassed 40 million, underscoring the clinical stakes of any resistance finding
A Stanford Medicine report indicates that approximately 1 in 10 people may carry some form of resistance to GLP-1 receptor agonist drugs, a widely prescribed class of type 2 diabetes medications. The headline figure, published under the title "One in 10 people may have resistance to GLP-1 diabetes drugs," frames the finding as a preliminary observation about why these blockbuster drugs do not work equally well for every patient.
What are GLP-1 drugs?
GLP-1 receptor agonists mimic a gut hormone called glucagon-like peptide 1. The class includes semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss, and tirzepatide, marketed as Mounjaro and Zepbound. These medications lower blood sugar, slow digestion, and reduce appetite. Doctors also prescribe them because they help patients lose weight and may protect the heart.
What does "resistance" mean here?
In diabetes care, resistance generally describes a situation in which a patient's blood sugar, weight, or other clinical markers do not improve as expected after starting a medication. Clinicians usually judge response by hemoglobin A1C, a blood test that reflects average blood sugar over roughly three months. A drop of at least 1 percentage point counts as clinically meaningful.
Why does the 10% figure matter?
Type 2 diabetes affects more than 500 million adults worldwide, according to the International Diabetes Federation. If 10% of those patients experience reduced benefit from GLP-1 drugs, that translates into tens of millions of people who could need alternative therapies, higher doses, or combination treatments. The economic and clinical stakes are large: GLP-1 prescriptions have surged past 40 million in the United States alone.
What might explain poor response?
Researchers have proposed several mechanisms for reduced effectiveness:
- Genetic variants in the GLP-1 receptor gene that change how the receptor binds the drug
- Differences in baseline gut hormone levels or downstream signaling
- Antibody formation against the drug after months of use
- Longer disease duration, since patients with advanced type 2 diabetes have fewer functioning insulin-producing beta cells
- Lifestyle factors, including diet, sleep, and physical activity
Stanford investigators have previously published on genetic predictors of obesity drug response, including work on the MC4R gene, though the specific authors of the new resistance report are not named in the publicly available headline.
What we still don't know
The Stanford Medicine announcement, as circulated in headline form, does not specify the study size, the genetic markers examined, or the threshold used to label a patient as "resistant." Readers should treat the 10% figure as a working estimate rather than a confirmed statistic. Full peer review and methodology details are needed before clinicians can act on the result.
What should patients do now?
Anyone taking a GLP-1 medication who feels the drug is not working should raise the issue with their prescriber. Standard alternatives for non-responders include SGLT2 inhibitors, DPP-4 inhibitors, or insulin. Dose escalation, switching within the GLP-1 class, or adding a complementary drug such as metformin remain common clinical strategies.
Until Stanford Medicine publishes the full study, the central message is straightforward: GLP-1 drugs help most patients, but a meaningful minority may need a different plan.
via Google News: Clinical Trials (Source)
More from James Calloway
Show full bio
Staff writer covering marketplaces and e-commerce at SciBeat.
205 articles
Nearby plates
- Cleveland Clinic Examines What Happens After GLP-1 Discontinuation
- Quitting Ozempic for Two Years Raises Heart Risk by 22%
- GLP-1 Diabetes Drugs Show Real-World Benefits in Young People
- Amylin Drug Petrelintide Delivers Over 10% Weight Loss
- GLP-1 Weight-Loss Drugs Work Similarly Across Age, Race, and Weight